# Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant

> **NCT00099736** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 696 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids
- **DRUG:** FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids
- **DRUG:** MMF 2 g + full-dose Neoral (FDN) + corticosteroids

## Key facts

- **NCT ID:** NCT00099736
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05-07
- **Primary completion:** 2005-09-19
- **Final completion:** 2005-09-19
- **Target enrollment:** 696 (ACTUAL)
- **Last updated:** 2017-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00099736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00099736, "Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00099736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*